NCT01596114CompletedPhase 3
Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukemia After Stopping TKI
European LeukemiaNet99 sites in 10 countries868 target enrollmentStarted: May 30, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 868
- Locations
- 99
- Primary Endpoint
- molecular relapse-free survival
Study Overview
Brief Summary
The EURO-SKI is a multicenter open label, uncontrolled trial estimating the persistence of molecular remission in Chronic Myeloid Leukemia (CML) patients after stopping Tyrosine Kinase Inhibitor (TKI). Main goal is the assessment of the duration of major molecular response (MMR) or better after stopping TKI therapy.
Secondary goals include:
- Identification of clinical and biological factors affecting the persistence of complete molecular remission after stopping TKI (e.g. level of Complete molecular remission (CMR), risk score, duration of TKI treatment, type of TKI pretreatment)
- Evaluation of quality of life (QoL) in patients stopping TKI
- Evaluation of medico-economic impact of stopping TKI
- Estimating the number of patients in CMR who are eligible for stopping TKI therapy by setting up a screening log
- Time to recovery of CMR There will be no randomised comparison. Based on the experience of the STIM trial (Mahon et al., Lancet Onc 2010) we expect an overall six-month molecular-relapse-free survival probability of at least 40%. An interim analysis will be performed after a pilot phase where 200 patients have been observed for at least six months. Formally, it is planned to test the null hypothesis H0: Six-month molecular relapse-free survival probability P ≤ 40% against the alternative hypothesis H1: Six-month molecular-relapse-free survival probability P > 40%. Eligible are adult CML patients in chronic phase on TKI treatment in CMR for at least one year (> 4 log reduction of BCR-ABL transcripts on IS, TKI treatment for at least 3 years, confirmed by a PCR within a standardized CMR laboratory). Clinical and biological monitoring will be performed during 3 years: Associated scientific projects are performed. Recruitment period: 2 years; follow up: 3 years. Planned patient recruitment in main phase: n=500
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •CML in CP under treatment with TKI in first line or in second line because of toxicity to first line TKI or with TKI in combination
- •Duration of TKI treatment before enrolment at least 3 years
- •At least complete molecular remission MR4
- •Before inclusion confirmation of CMR4 through a EUTOS-CMR laboratory
- •Baseline data and documentation on treatment before study entry available
- •Both sexes but fertile women only if using effective contraceptive
- •Health insurance coverage
- •18 years or older
Exclusion Criteria
- •Under 18 years old
- •Hospitalized patients without ability to give informed consent
- •Adults under law protection or without ability to consent
- •Previous or planned allogeneic stem cell transplantation
Outcomes
Primary Outcomes
molecular relapse-free survival
Time Frame: 3 years
Evaluation of molecular relapse-free survival after stopping TKI (survival without molecular relapse defined by BCR-ABL1 \> 0.1% on the IS at one time point (loss of major molecular response, MMR))
Secondary Outcomes
- QoL(3 years)
- Time to recovery(3 years)
- Overall and progression-free survival(3 years)
- Treatment costs(3 years)
Investigators
Study Sites (99)
Loading locations...
Similar Trials
Completed
Phase 3
Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689DiabetesDiabetes Mellitus, Type 1NCT00623194Novo Nordisk A/S146
Completed
Phase 4
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01704378Novo Nordisk A/S89
Completed
Phase 1
Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male VolunteersHealthyDiabetesNCT01511159Novo Nordisk A/S32
Completed
Phase 1
Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia ACongenital Bleeding DisorderHaemophilia ANCT01692925Novo Nordisk A/S15
Completed
Not Applicable
Randomised prospective European Multicenter Oscillator Acute Respiratory Distress Syndrome (ARDS) TrialISRCTN24242669SensorMedics (USA)61